Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1521 clinical trials
Featured trial
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will

mercaptopurine
dexamethasone
cytarabine
thioguanine
cyclophosphamide
  • 5 views
  • 04 Oct, 2022
  • 98 locations
Featured trial
A Study Evaluating Safety and Tolerability and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

neoplasm (MPN) or chronic myelomonocytic leukemia (CMML).

chronic myelomonocytic leukemia
polycythemia
essential thrombocythemia
thrombocytosis
leukemia
  • 49 views
  • 17 Sep, 2022
  • 36 locations
Featured trial
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Background: Chronic lymphocytic leukemia (CLL) is a cancer of white blood cells. It is also called small lymphocytic lymphoma (SLL). It causes tiredness, night sweats

lymphadenopathy
ibrutinib
neutrophil count
chronic lymphocytic leukemia
lymphoma
  • 359 views
  • 23 Nov, 2020
  • 1 location
Featured trial
Response to the HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients that are Treatment Naive or Receiving Bruton s-tyrosine Kinase Inhibitor (BTK-I) Therapy

Background: People with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) tend to get infections more easily. This is because their immune

acalabrutinib
chronic lymphocytic leukemia
lymphoma
ibrutinib
  • 67 views
  • 09 Apr, 2019
  • 1 location
Featured trial
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients that are Treatment Naive or Receiving Bruton s-Tyrosine Kinase Inhibitor (BTK-I) Therapy

. Scientists had thought people with chronic lymphocytic leukemia (CLL) should not get the shingles vaccine. Now there is a new shingles vaccine that is not live and cannot cause shingles. The new shingles

ibrutinib
chronic lymphocytic leukemia
lymphoma
cancer
acalabrutinib
  • 238 views
  • 09 Apr, 2019
  • 1 location
Featured trial
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL), Lymphoplasmacytic Lymphoma(LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma(SMZL)

(MBL), chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Applying these

lymphadenopathy
chronic lymphocytic leukemia
lymphoma
cancer
waldenstrom's macroglobulinemia
  • 115 views
  • 15 Apr, 2019
  • 1 location
Featured trial
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Background: Chronic lymphocytic leukemia (CLL) and/or small lymphocytic lymphoma (SLL) are tumors of abnormal B cells that often affect elderly patients. Studies have

lymphadenopathy
ibrutinib
chronic lymphocytic leukemia
lymphoma
anemia
  • 169 views
  • 15 Apr, 2019
  • 1 location
Featured trial
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with low-dose ruxolitinib or itacitinib alone in subjects with myelofibrosis.   This is an open-label Phase 2 study with 2 cohorts: Cohort A: Itacitinib plus ruxolitinib  Drug: Itacitinib self-administered orally once daily at the   protocol-defined …

myeloproliferative disorders
leukemia
myelofibrosis
  • 172 views
  • 10 May, 2022
  • 9 locations
Featured trial
AALL08B1: Risk-Based Classification System of Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

AALL08B1: Risk-Based Classification System of Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

  • 112 views
  • 08 Nov, 2020
  • 1 location
Featured trial
AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)

AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)

  • 112 views
  • 08 Nov, 2020
  • 1 location